Download Image
    
Share
  
Post
Iodine for COVID-19
1 study with 141 patients
Hospital Icon Control
Hospital Icon Iodine Serious Outcome Risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Iodine studies. Mar 2026. c19early.org
0 0.5 1 1.5+ All studies -10% Mortality -10% RCTs -10% Late -10% Favorsiodine Favorscontrol
Recent:
Traksel.
Feb 2
 Traksel et al., PLOS One, doi:10.1371/journal.pone.0341126 Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial
10% higher mortality (p=0.83), 34% lower ventilation (p=0.44), and 30% lower ICU admission (p=0.46). RCT 141 hospitalized COVID-19 patients showing no significant difference in mortality or ICU admission with 12.5 mg daily oral iodine for 8 days. Exploratory analysis found patients receiving iodine had significantly shorter ICU stays.